Global Skin Cancer Molecular Diagnostics Market Size is poised to Reach USD 25.50 Billion by 2035 | CAGR of 14.79%
Category: HealthcareGlobal Skin Cancer Molecular Diagnostics Market Size is poised to Reach USD 25.50 Billion by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Skin Cancer Molecular Diagnostics Market Size is expected to Grow from USD 5.59 Billion in 2024 to USD 25.50 Billion by 2035, at a CAGR of 14.79% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Skin Cancer Molecular Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Cancer Type (Melanoma and Non-Melanoma), By End-User (Hospitals & Diagnostic Laboratories, Research Institutions & Academic Labs, and Pharmaceutical & Biotech Companies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/skin-cancer-molecular-diagnostics-market
The skin cancer molecular diagnostics market refers to the use of genetic testing (DNA/RNA) and biomarkers to detect, classify, and guide treatment for skin cancers like melanoma and non-melanoma. Skin cancer is a significant and increasing global health burden; the current diagnostic workflow is able to provide clinically actionable results with significant training and expertise as well as patient accessibility to the workflow. Molecular biomarkers are transforming the diagnostics and treatment delivery in oncology. There are commercially available, clinically validated, and emerging skin cancer molecular biomarkers are reviewed. The growing R&D expenditure and expanding product pipelines, and partnerships among key market players are strengthening the market presence. Furthermore, small biotech firms and stratups emphasizing innovation in liquid biopsy solutions products, which aid in gaining market share in the niche segments. An increasing skin cancer prevalence is anticipated to drive the skin cancer molecular diagnostics market, with skin cancers as the most common group of cancer diagnosed worldwide, with more than 1.5 million new cases estimated in 2022. Advancements in molecular diagnostics, along with an increased emphasis on personalized medicine concept, play an important role in accelerating the market growth. However, increased costs and technical limitations, as well as regulatory barriers. Limited availability of healthcare infrastructure is challenging the market.
The non-melanoma segment dominated the market with nearly 75% share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the cancer type, the Skin cancer molecular diagnostics market is divided into melanoma and non-melanoma. Among these, the non-melanoma segment dominated the market with nearly 75% share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Molecular diagnosis of NMSC (including basal cell and squamous cell carcinoma), emphasizing identification of UV-induced genetic mutations and protein markers for improved and early detection. It was found that non-melanoma skin cancer causes more deaths each year, as an aggressive form of skin cancer, which may be the reason for increased market segmental growth.
The hospitals and diagnostic laboratories segment accounted for the largest share of over 65% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the end-user, the skin cancer molecular diagnostics market is divided into hospitals & diagnostic laboratories, research institutions & academic labs, and pharmaceutical & biotech companies. Among these, the hospitals and diagnostic laboratories segment accounted for the largest share of over 65% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. This includes Immunohistochemistry (IHC), next-generation sequencing (NGS), and gene expression profiling GEP for identifying specific molecular changes. The presence of advanced techniques in hospitals, which are beyond traditional pathology are responsible for driving the market.
North America is expected to hold the majority share of over 45% in the global skin cancer molecular diagnostics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of over 45% in the global skin cancer molecular diagnostics market during the forecast period. The U.S. is estimated to account for about 87% of the regional skin cancer molecular diagnostics market due to several reasons, including skin cancer incidence, advanced diagnostic infrastructure, string reimbursement system, presence of biotech & diagnostic players, and greater awareness & screening programs. With both cutting-edge startups and major industrial heavyweights well-represented, like VivoSight and Veriskin, Inc., the North America market growth is strong. Further, the region's increased awareness of precision oncology approaches and advanced healthcare infrastructure is accelerating the market growth.
Asia Pacific is anticipated to grow at the fastest pace with an estimated 11.7% CAGR in the global skin cancer molecular diagnostics market during the forecast period. China is the fastest growing country in APAC skin cancer molecular diagnostics market, due to the increased cases of MSM related deaths. The market growth is supported by expanding healthcare accessibility, awareness campaigns, and government-backed precision medicine initiatives. The region's increasing use of solutions like biomaterials and artificial intelligence (AI), as well as international skin consortiums forming to bridge academia and industry in new collaborations, is expected to propel the regional market growth for skin cancer molecular diagnostics.
Major vendors in the global skin cancer molecular diagnostics market are Annoroad, Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Qiagen, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In October 2025, DermaSensor, a Miami-based medical device technology company that aims to revolutionize skin cancer detection in primary care offices, announced it has raised $16 million in Series B funding.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Skin Cancer Molecular Diagnostics market based on the below-mentioned segments:
Global Skin Cancer Molecular Diagnostics Market, By Cancer Type
- Melanoma
- Non-Melanoma
Global Skin Cancer Molecular Diagnostics Market, By End-User
- Hospitals & Diagnostic Laboratories
- Research Institutions & Academic Labs
- Pharmaceutical & Biotech Companies
Global Skin Cancer Molecular Diagnostics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?